On December 4, 2023, Nanobiotix S.A. closed the transaction. The company issued 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares at a price $5.36 for a gross proceeds $4,830,732.16 in its second and final tranche, the company has issued total 4,664,179 shares for total gross proceeds of $24,999,999.44 in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.45 EUR | +0.93% | +3.81% | -17.92% |
Apr. 25 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 | |
Apr. 24 | Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.92% | 274M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.